Cambios moleculares en la remodelación cardiaca por síndrome metabólico.

Autores:: Vargas López, Misael
Cortés Martínez, Edgar Fernando
Velázquez Domínguez, José Antonio

Tipo de recurso:: Article of journal

Fecha de publicación:: 2020

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_b231528b79619cbc67226c6e7d7db297
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13413
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
dc.title.translated.eng.fl_str_mv	Molecular changes in cardiac remodeling due to metabolic syndrome.
title	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
spellingShingle	Cambios moleculares en la remodelación cardiaca por síndrome metabólico. Cardiac remodeling Metabolic syndrome Obesity Diabetes Dyslipidemia Molecular biology Remodelación cardiaca Síndrome metabólico Obesidad Diabetes Dislipidemias Biología molecular
title_short	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
title_full	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
title_fullStr	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
title_full_unstemmed	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
title_sort	Cambios moleculares en la remodelación cardiaca por síndrome metabólico.
dc.creator.fl_str_mv	Vargas López, Misael Cortés Martínez, Edgar Fernando Velázquez Domínguez, José Antonio
dc.contributor.author.spa.fl_str_mv	Vargas López, Misael Cortés Martínez, Edgar Fernando Velázquez Domínguez, José Antonio
dc.subject.eng.fl_str_mv	Cardiac remodeling Metabolic syndrome Obesity Diabetes Dyslipidemia Molecular biology
topic	Cardiac remodeling Metabolic syndrome Obesity Diabetes Dyslipidemia Molecular biology Remodelación cardiaca Síndrome metabólico Obesidad Diabetes Dislipidemias Biología molecular
dc.subject.spa.fl_str_mv	Remodelación cardiaca Síndrome metabólico Obesidad Diabetes Dislipidemias Biología molecular
publishDate	2020
dc.date.accessioned.none.fl_str_mv	2020-07-15 00:00:00
dc.date.available.none.fl_str_mv	2020-07-15 00:00:00
dc.date.issued.none.fl_str_mv	2020-07-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2020-3160
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2020-3160
identifier_str_mv	2215-7840 10.32997/rcb-2020-3160 2389-7252
url	https://doi.org/10.32997/rcb-2020-3160
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3160/2687
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2020
dc.relation.citationendpage.none.fl_str_mv	146
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	131
dc.relation.citationvolume.spa.fl_str_mv	9
dc.relation.references.spa.fl_str_mv	Al-Daghri NM, Alkharfy KM, Al-Saleh Y, Al-Attas OS, Alokail MS, Al-Othman A, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: A 12-month prospective study. Metabolism [Internet]. 2012; 61(5): 661-6. https://doi.org/10.1016/j.metabol.2011.09.017 Tadic M, Cuspidi C. Childhood obesity and cardiac remodeling: From cardiac structure to myocardial mechanics. J Cardiovasc Med. 2015;16(8):538-46. https://doi.org/10.2459/JCM.0000000000000261 XuZ,SunJ,TongQ,LinQ,QianL,ParkY,etal.The role of ERK1/2 in the development of diabetic cardiomyopathy. Int J Mol Sci. 2016;17(12):1-17. https://doi.org/10.3390/ijms17122001 Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, et al. Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension. 2015;66(5):961- 9. https://doi.org/10.1161/HYPERTENSIONAHA.115.06032 De Boer RA, V an Der V elde AR. Galectin-3: A new biomarker for heart failure progression and prognosis. Laboratoriums Medizin. 2013;37(5):251-60. https://doi.org/10.1515/labmed-2012-0073 Bobronnikova L. Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes. Vessel Plus. 2017;1(2):61-7. https://doi.org/10.20517/2574-1209.2016.10 Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract [Internet]. 2017; 133: 124-30. Available from: https://doi.org/10.1016/j.diabres.2017.08.018 Liu G, Ma C, Yang H, Zhang PY. Transforming growth factor β and its role in heart disease. Exp Ther Med. 2017;13(5):2123-8. https://doi.org/10.3892/etm.2017.4246 Liu X, Liang E, Song X, Du Z, Zhang Y, Zhao Y. Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice. Biochem Biophys Res Commun 2016; 479(1): 109-15. https://doi.org/10.1016/j.bbrc.2016.09.050 Shaker YM, Soliman HA, Ezzat E, Hussein NS, Ashour E, Donia A, et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients. Beni-Suef Univ J Basic Appl Sci. 2014;3(1):16-23. https://doi.org/10.1016/j.bjbas.2014.02.002 Huang GL, Qiu JH, Li BBin, Wu JJ, Lu Y, Liu XY, et al. Prolyl isomerase pin1 regulated signaling pathway revealed by pin1 +/+ and Pin1 -/- mouse embryonic fibroblast cells. Pathol Oncol Res. 2013; 19(4): 667-75. https://doi.org/10.1007/s12253-013-9629-x Turner, Blythe. Cardiac Fibroblast p38 MAPK: A Critical Regulator of Myocardial Remodeling. J Cardiovasc Dev Dis. 2019;6(3):27. https://doi.org/10.3390/jcdd6030027 Muslin JA. MAPK Signaling in cardiovascular health and desease: Molecular mechanism and therapeutic targets. Clin Sci. 2009;115(7):203-18. https://doi.org/10.1042/CS20070430 Wang S, Ding L, Ji H, Xu Z, Liu Q, Zheng Y. Therole of p38 MAPK in the development of diabetic cardiomyopathy. Int J Mol Sci. 2016;17(7):1-14. https://doi.org/10.3390/ijms18010001 Craige SM, Chen K, Blanton RM, Keaney JF, Kant S. JNK and cardiometabolic dysfunction. Biosci Rep. 2019;39(7):1-18. https://doi.org/10.1042/BSR20190267 Pal M, Febbraio MA, Lancaster GI. The roles of c-Jun NH2-terminal kinases (JNKs) in obesity and insulin resistance. J Physiol. 2016; 594(2): 267-79. https://doi.org/10.1113/JP271457 Schumacher-Bass SM, Traynham CJ, Koch WJ. G protein-coupled receptor kinase 2 as a therapeutic target for heart failure. Drug Discov Today Ther Strateg. 2012;9(4):1-14. https://doi.org/10.1016/j.ddstr.2014.01.002 Woodall MC, Ciccarelli M, Woodall BP, Koch WJ. GRK2 - A Link Between Myocardial Contractile Function and Cardiac Metabolism. Circ Res. 2014;114(10):1661-70. https://doi.org/10.1161/CIRCRESAHA.114.300513 Goncąlves N, Falcaõ-Pires I, Leite-Moreira AF. Adipokines and their receptors: Potential new targets in cardiovascular diseases. Future Med Chem. 2015;7(2):139-57. https://doi.org/10.4155/fmc.14.147 Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: An update. Br J Pharmacol. 2012;165(3):574-90. https://doi.org/10.1111/j.1476-5381.2011.01395.x Imo A. E, David C. GJ, Carlos J. R, Haiying C, Alain G. B. Mechanisms of heart failure in obesity. Obes Res Clin Pr. 2014;8(6):e540-8. https://doi.org/10.1016/j.orcp.2013.12.005 Katsiki N, Mikhailidis DP , Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus review-article. Acta Pharmacol Sin. 2018;39(7):1176-88. https://doi.org/10.1038/aps.2018.40 Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, et al. NF-kβ and AP-1 Connection : Mechanism of NF-kβ Dependent Regulation of AP-1 Activity. 2004; 24(17): 7806-19. https://doi.org/10.1128/MCB.24.17.7806-7819.2004 Craig R, Wagner M, McCardle T, Craig AG, Glembotski CC. The Cytoprotective Effects of the Glycoprotein 130 Receptor-coupled Cytokine, Cardiotrophin-1, Require Activation of NF-κB. J Biol Chem. 2001;276(40):37621- 9. https://doi.org/10.1074/jbc.M103276200 Hernández-Gutiérrez S, Rojas-del Castillo E. edigraphic.com. El Pap del factor transcripción NF-κB en la célula cardíaca. 2005;75:363-70. Higuchi M, Manna SK, Sasaki R, Aggarwal BB. Regulation of the activation of nuclear factor κB by mitochondrial respiratory function: Evidence for the reactive oxygen species-dependent and -independent pathways. Antioxidants Redox Signal. 2002; 4(6): 945-55. https://doi.org/10.1089/152308602762197489 Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A. 2001;98(12):6668-73. https://doi.org/10.1073/pnas.111155798 Park KR, Kwon MS, An JY, Lee JG, Youn HS, Lee Y, et al. Structural implications of Ca2+-dependent actin- bundling function of human EFhd2/Swiprosin-1. Sci Rep. 2016;6(July):1-15. https://doi.org/10.1038/srep39095 Huh YH, Kim SH, Chung KH, Oh S, Kwon MS, Choi HW, et al. Swiprosin-1 modulates actin dynamics by regulating the F-actin accessibility to cofilin. Cell Mol Life Sci. 2013; 70(24): 4841-54. https://doi.org/10.1007/s00018-013-1447-5 Schreckenberg R, Pöling J, Lörchner H. Swiprosin- 1/EFhD-2 Expression in Cardiac Remodeling and Post- Infarct Repair : Effect of Ischemic Conditioning. 2020; 2: 1-13. Nippert F, Schreckenberg R, Hess A, Weber M, Schlüter KD. The effects of swiprosin-1 on the formation of pseudopodia-like structures and β- adrenoceptor coupling in cultured adult rat ventricular cardiomyocytes. PLoS One. 2016; 11(12): 1-15. https://doi.org/10.1371/journal.pone.0167655
dc.rights.spa.fl_str_mv	Revista Ciencias Biomédicas - 2020
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Revista Ciencias Biomédicas - 2020 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3160
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/0182e198-8d9e-4738-a336-fb50972de8c7/download
bitstream.checksum.fl_str_mv	5902e8537d25f33a7e9ab79b5599b418
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814214207520899072
spelling	Vargas López, MisaelCortés Martínez, Edgar FernandoVelázquez Domínguez, José Antonio2020-07-15 00:00:002020-07-15 00:00:002020-07-152215-784010.32997/rcb-2020-31602389-7252https://doi.org/10.32997/rcb-2020-3160application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3160/2687Núm. 2 , Año 202014621319Al-Daghri NM, Alkharfy KM, Al-Saleh Y, Al-Attas OS, Alokail MS, Al-Othman A, et al. Modest reversal of metabolic syndrome manifestations with vitamin D status correction: A 12-month prospective study. Metabolism [Internet]. 2012; 61(5): 661-6. https://doi.org/10.1016/j.metabol.2011.09.017Tadic M, Cuspidi C. Childhood obesity and cardiac remodeling: From cardiac structure to myocardial mechanics. J Cardiovasc Med. 2015;16(8):538-46. https://doi.org/10.2459/JCM.0000000000000261XuZ,SunJ,TongQ,LinQ,QianL,ParkY,etal.The role of ERK1/2 in the development of diabetic cardiomyopathy. Int J Mol Sci. 2016;17(12):1-17. https://doi.org/10.3390/ijms17122001Martínez-Martínez E, López-Ándres N, Jurado-López R, Rousseau E, Bartolomé MV, Fernández-Celis A, et al. Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension. 2015;66(5):961- 9. https://doi.org/10.1161/HYPERTENSIONAHA.115.06032De Boer RA, V an Der V elde AR. Galectin-3: A new biomarker for heart failure progression and prognosis. Laboratoriums Medizin. 2013;37(5):251-60. https://doi.org/10.1515/labmed-2012-0073Bobronnikova L. Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes. Vessel Plus. 2017;1(2):61-7. https://doi.org/10.20517/2574-1209.2016.10Yue Y, Meng K, Pu Y, Zhang X. Transforming growth factor beta (TGF-β) mediates cardiac fibrosis and induces diabetic cardiomyopathy. Diabetes Res Clin Pract [Internet]. 2017; 133: 124-30. Available from: https://doi.org/10.1016/j.diabres.2017.08.018Liu G, Ma C, Yang H, Zhang PY. Transforming growth factor β and its role in heart disease. Exp Ther Med. 2017;13(5):2123-8. https://doi.org/10.3892/etm.2017.4246Liu X, Liang E, Song X, Du Z, Zhang Y, Zhao Y. Inhibition of Pin1 alleviates myocardial fibrosis and dysfunction in STZ-induced diabetic mice. Biochem Biophys Res Commun 2016; 479(1): 109-15. https://doi.org/10.1016/j.bbrc.2016.09.050Shaker YM, Soliman HA, Ezzat E, Hussein NS, Ashour E, Donia A, et al. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients. Beni-Suef Univ J Basic Appl Sci. 2014;3(1):16-23. https://doi.org/10.1016/j.bjbas.2014.02.002Huang GL, Qiu JH, Li BBin, Wu JJ, Lu Y, Liu XY, et al. Prolyl isomerase pin1 regulated signaling pathway revealed by pin1 +/+ and Pin1 -/- mouse embryonic fibroblast cells. Pathol Oncol Res. 2013; 19(4): 667-75. https://doi.org/10.1007/s12253-013-9629-xTurner, Blythe. Cardiac Fibroblast p38 MAPK: A Critical Regulator of Myocardial Remodeling. J Cardiovasc Dev Dis. 2019;6(3):27. https://doi.org/10.3390/jcdd6030027Muslin JA. MAPK Signaling in cardiovascular health and desease: Molecular mechanism and therapeutic targets. Clin Sci. 2009;115(7):203-18. https://doi.org/10.1042/CS20070430Wang S, Ding L, Ji H, Xu Z, Liu Q, Zheng Y. Therole of p38 MAPK in the development of diabetic cardiomyopathy. Int J Mol Sci. 2016;17(7):1-14. https://doi.org/10.3390/ijms18010001Craige SM, Chen K, Blanton RM, Keaney JF, Kant S. JNK and cardiometabolic dysfunction. Biosci Rep. 2019;39(7):1-18. https://doi.org/10.1042/BSR20190267Pal M, Febbraio MA, Lancaster GI. The roles of c-Jun NH2-terminal kinases (JNKs) in obesity and insulin resistance. J Physiol. 2016; 594(2): 267-79. https://doi.org/10.1113/JP271457Schumacher-Bass SM, Traynham CJ, Koch WJ. G protein-coupled receptor kinase 2 as a therapeutic target for heart failure. Drug Discov Today Ther Strateg. 2012;9(4):1-14. https://doi.org/10.1016/j.ddstr.2014.01.002Woodall MC, Ciccarelli M, Woodall BP, Koch WJ. GRK2 - A Link Between Myocardial Contractile Function and Cardiac Metabolism. Circ Res. 2014;114(10):1661-70. https://doi.org/10.1161/CIRCRESAHA.114.300513Goncąlves N, Falcaõ-Pires I, Leite-Moreira AF. Adipokines and their receptors: Potential new targets in cardiovascular diseases. Future Med Chem. 2015;7(2):139-57. https://doi.org/10.4155/fmc.14.147Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: An update. Br J Pharmacol. 2012;165(3):574-90. https://doi.org/10.1111/j.1476-5381.2011.01395.xImo A. E, David C. GJ, Carlos J. R, Haiying C, Alain G. B. Mechanisms of heart failure in obesity. Obes Res Clin Pr. 2014;8(6):e540-8. https://doi.org/10.1016/j.orcp.2013.12.005Katsiki N, Mikhailidis DP , Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus review-article. Acta Pharmacol Sin. 2018;39(7):1176-88. https://doi.org/10.1038/aps.2018.40Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, et al. NF-kβ and AP-1 Connection : Mechanism of NF-kβ Dependent Regulation of AP-1 Activity. 2004; 24(17): 7806-19. https://doi.org/10.1128/MCB.24.17.7806-7819.2004Craig R, Wagner M, McCardle T, Craig AG, Glembotski CC. The Cytoprotective Effects of the Glycoprotein 130 Receptor-coupled Cytokine, Cardiotrophin-1, Require Activation of NF-κB. J Biol Chem. 2001;276(40):37621- 9. https://doi.org/10.1074/jbc.M103276200Hernández-Gutiérrez S, Rojas-del Castillo E. edigraphic.com. El Pap del factor transcripción NF-κB en la célula cardíaca. 2005;75:363-70.Higuchi M, Manna SK, Sasaki R, Aggarwal BB. Regulation of the activation of nuclear factor κB by mitochondrial respiratory function: Evidence for the reactive oxygen species-dependent and -independent pathways. Antioxidants Redox Signal. 2002; 4(6): 945-55. https://doi.org/10.1089/152308602762197489Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A. 2001;98(12):6668-73. https://doi.org/10.1073/pnas.111155798Park KR, Kwon MS, An JY, Lee JG, Youn HS, Lee Y, et al. Structural implications of Ca2+-dependent actin- bundling function of human EFhd2/Swiprosin-1. Sci Rep. 2016;6(July):1-15. https://doi.org/10.1038/srep39095Huh YH, Kim SH, Chung KH, Oh S, Kwon MS, Choi HW, et al. Swiprosin-1 modulates actin dynamics by regulating the F-actin accessibility to cofilin. Cell Mol Life Sci. 2013; 70(24): 4841-54. https://doi.org/10.1007/s00018-013-1447-5Schreckenberg R, Pöling J, Lörchner H. Swiprosin- 1/EFhD-2 Expression in Cardiac Remodeling and Post- Infarct Repair : Effect of Ischemic Conditioning. 2020; 2: 1-13.Nippert F, Schreckenberg R, Hess A, Weber M, Schlüter KD. The effects of swiprosin-1 on the formation of pseudopodia-like structures and β- adrenoceptor coupling in cultured adult rat ventricular cardiomyocytes. PLoS One. 2016; 11(12): 1-15. https://doi.org/10.1371/journal.pone.0167655Revista Ciencias Biomédicas - 2020https://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3160Cardiac remodelingMetabolic syndromeObesityDiabetesDyslipidemiaMolecular biologyRemodelación cardiacaSíndrome metabólicoObesidadDiabetesDislipidemiasBiología molecularCambios moleculares en la remodelación cardiaca por síndrome metabólico.Molecular changes in cardiac remodeling due to metabolic syndrome.Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2524https://repositorio.unicartagena.edu.co/bitstreams/0182e198-8d9e-4738-a336-fb50972de8c7/download5902e8537d25f33a7e9ab79b5599b418MD5111227/13413oai:repositorio.unicartagena.edu.co:11227/134132024-09-05 15:30:47.809https://creativecommons.org/licenses/by-nc-sa/4.0/Revista Ciencias Biomédicas - 2020metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Cambios moleculares en la remodelación cardiaca por síndrome metabólico.

Publicaciones similares